Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.

Clinica chimica acta; international journal of clinical chemistry - 20 Jan 2014

Hwang In Cheol, Park Ji Young, Ahn Hong Yup, Kim Kyoung Kon, Suh Heuy Sun, Ko Ki Dong, Kim Kyoung-Ah

Abstract excerpt

BACKGROUND: Various cytochrome P450 isoforms modulate sibutramine activity and influence sibutramine plasma levels and pharmacokinetics. However, there are no available data to demonstrate the association of these polymorphisms with the clinical outcomes of sibutramine administration. METHODS: This study was a sub-investigation of a 12-week, double-blind, placebo-controlled trial examining the additive effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2B6
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Double-Blind Method

Share to Heart Rate

Share to Lactones

Share to Regression Analysis

Share to Weight Loss

Source

Identifiers

PMID: 24262967
DOI: 10.1016/j.cca.2013.11.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.PMID 24262967Read ↗

Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects.Semantic proximity Read ↗

Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.Semantic proximity Read ↗

A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.Semantic proximity Read ↗

Pharmacogenetics of obesity drug therapy.Semantic proximity Read ↗

Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.Semantic proximity Read ↗

Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.Semantic proximity Read ↗

Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1.Semantic proximity Read ↗

Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.Semantic proximity Read ↗

Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.Semantic proximity Read ↗

Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.Semantic proximity Read ↗

Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites.Semantic proximity Read ↗

Cardiovascular Effects and Safety of Lisdexamfetamine in Attention-Deficit/Hyperactivity Disorder and Healthy Volunteers: A Systematic Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.